A Multicenter, Randomized, Double blind, Placebo controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Antimalarial Therapy
Cutaneous lupus erythematosus
18 Years - 70 Years
Endpoint Classification: -
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Verified 01 Sept 2023 by AstraZeneca
No locations available
The participants will receive dose A of anifrolumab as a SC injection from Week 0/Day 1 upto and including week 51.
Combination Product: Anifrolumab
Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).
|Placebo Comparator: Placebo|
The participant will receive placebo as a SC injection from Week 0/Day 1 to Week 23. From Week 24 the participants will receive dose A of anifrolumab up to and including Week 51.
Matching placebo solution for injection in aPFS.